
Opinion|Videos|May 22, 2025
Leveraging Genomic Assays to Guide Treatment Decisions: Clinical Scenarios and Expert Perspectives
Panelists discuss how genomic testing informs real clinical scenarios, demonstrating that for a 64-year-old healthy woman with a single positive lymph node, the 21-gene assay would guide treatment decisions, with cardiac assessment influencing whether anthracycline-based chemotherapy would be used if her score was high.
Advertisement
Evolving Paradigms and Future Directions
Main Discussion Topics:
- Changing patterns in breast cancer mortality by stage at diagnosis
- Challenges in identifying high-risk early-stage patients
- Future directions for research and treatment optimization
Key Points for Physicians:
- Research findings show that 62% of patients who died from breast cancer in 2017 initially presented with stage I-II disease.
- Current research focuses on identifying early-stage patients who need more aggressive treatment.
- Questions remain about optimal treatment approaches (anthracyclines vs CDK4/6 inhibitors).
Notable Insights:
- The proportional risk reduction from current treatments has been greater for stage III-IV disease than for stage I-II disease.
- Clinical trial design faces challenges in asking the right questions rather than simply adding therapies.
Clinical Significance: Despite progress in breast cancer treatment, a significant unmet need remains in identifying and effectively treating early-stage patients at highest risk for recurrence and mortality.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

